Zevra Therapeutics (ZVRA) Enterprise Value (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Enterprise Value of -$200.6 million for Q1 2026, down 5.03% on a QoQ basis from -$191.0 million in Q4 2025, and down 220.31% year-over-year from $166.7 million in Q1 2025.
Zevra Therapeutics (ZVRA) Enterprise Value (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$200.6 million for Q1 2026.
- Quarterly Enterprise Value fell 220.31% year-over-year to -$200.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$200.6 million (down 220.31% YoY) and the FY2025 annual result came in at -$191.0 million, down 174.85% from the prior year.
- Enterprise Value was -$200.6 million for Q1 2026 at Zevra Therapeutics, down from -$191.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$479000.0 in Q2 2023 and bottomed at -$202.6 million in Q2 2025.
- A 5-year average of -$92.6 million and a median of -$68.6 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 99.38% — and 2024, when it tumbled 10183.51%.
- Zevra Therapeutics' Enterprise Value stood at -$65.9 million in 2022, then decreased by 2.71% to -$67.7 million in 2023, then retreated by 2.6% to -$69.5 million in 2024, then plunged by 174.85% to -$191.0 million in 2025, then decreased by 5.03% to -$200.6 million in 2026.
- Business Quant data shows ZVRA's Enterprise Value at -$200.6 million in Q1 2026, -$191.0 million in Q4 2025, and -$199.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | -200.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -200.62 Mn |
| Dec 31, 2025 | -191.01 Mn |
| Sep 30, 2025 | -199.51 Mn |
| Jun 30, 2025 | -202.61 Mn |
| Mar 31, 2025 | -62.63 Mn |
| Dec 31, 2024 | -69.50 Mn |
| Sep 30, 2024 | -89.38 Mn |
| Jun 30, 2024 | -49.26 Mn |
| Mar 31, 2024 | -52.72 Mn |
| Dec 31, 2023 | -67.74 Mn |
| Sep 30, 2023 | -43.27 Mn |
| Jun 30, 2023 | -479,000.00 |
| Mar 31, 2023 | -40.18 Mn |
| Dec 31, 2022 | -65.95 Mn |
| Sep 30, 2022 | -70.06 Mn |
| Jun 30, 2022 | -76.78 Mn |
| Dec 31, 2021 | -112.35 Mn |
| Sep 30, 2021 | -131.50 Mn |
| Jun 30, 2021 | -132.30 Mn |
| Mar 31, 2021 | -75.92 Mn |